Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Allergic Contact Dermatitis
NCT03935971Phase 4Active, not recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in allergic contact dermatitis (ACD), sponsored by Brigham and Women's Hospital. Started Dec 2019; status: active, not recruiting.
02
Drugs
03
Conditions
allergic contact dermatitis (ACD)
Beyond the preview
Go deeper on NCT03935971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935971.